N. Ktorza

发表

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A highly virulent variant of HIV-1 circulating in the Netherlands

Michael J. Rausch, H. Jessen, A. Trkola, 2022, Science.

Foscarnet Salvage Therapy for Patients with Late-Stage HIV Disease and Multiple Drug Resistance

V. Calvez, C. Katlama, E. Caumes, 2005, Antiviral therapy.

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy *

V. Calvez, C. Delaugerre, C. Katlama, 2004, HIV medicine.

Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

V. Calvez, C. Delaugerre, C. Katlama, 2003, Antimicrobial Agents and Chemotherapy.

Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies.

V. Calvez, R. Tubiana, C. Katlama, 2013, The Journal of antimicrobial chemotherapy.

Efficacy and safety of tenofovir double‐dose in treatment‐experienced HIV‐infected patients: The tenoplus study

V. Calvez, C. Katlama, G. Peytavin, 2007, Journal of medical virology.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

Vincent Calvez, Christine Katlama, V. Calvez, 2005, AIDS.

Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy

V. Calvez, C. Delaugerre, C. Katlama, 2004, Antimicrobial Agents and Chemotherapy.

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.

D. Podzamczer, B. Clotet, A. Winston, 2020, The Journal of antimicrobial chemotherapy.

Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients

V. Calvez, C. Delaugerre, C. Katlama, 2004, Journal of medical virology.

Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients

C. Katlama, E. Caumes, M. Valantin, 2021, Infectious Diseases Now.

Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study

V. Calvez, C. Katlama, G. Peytavin, 2012, HIV clinical trials.

Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20

Sabine Yerly, Vincent Calvez, Christine Katlama, 2004, AIDS.

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial

C. Katlama, Y. Yazdanpanah, F. Raffi, 2021, AIDS Research and Therapy.